<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437330</url>
  </required_header>
  <id_info>
    <org_study_id>Oxidise</org_study_id>
    <nct_id>NCT03437330</nct_id>
  </id_info>
  <brief_title>Empagliflozin Effect on Glucose Toxicity</brief_title>
  <official_title>Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized,&#xD;
      open-label, controlled, parallel group, exploratory study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EMPA-REG outcome trial showed that empagliflozin on top of standard therapy for Type 2&#xD;
      diabetes mellitus (T2DM) resulted in superiority in terms of the primary composite&#xD;
      cardiovascular endpoint (hazard ratio (1) = 0.86; 95% confidence interval [CI] 0.74-0.99; P&#xD;
      value = 0.04), hospitalization for heart failure (-35%), cardiovascular mortality (-38%) and&#xD;
      all-cause mortality (-32%, each p &lt; 0.001) (2). This reduction in mortality is not fully&#xD;
      explained by the reduction in HbA1c, body weight, waist circumference and blood pressure in&#xD;
      the empagliflozin groups versus the placebo group. Differences in mode of action of&#xD;
      empagliflozin compared to standard therapy might, thus, help to explain why empagliflozin was&#xD;
      so efficient in reducing cardiovascular death.&#xD;
&#xD;
      The aim of the present study is to provide evidence for a reduction of skeletal muscle H2O2&#xD;
      levels, and consequently improvement in mitochondrial function, and restored methylation&#xD;
      pattern of key transcription factors in skeletal muscle from patients with T2DM when treated&#xD;
      with empagliflozin versus insulin glargine as the prototypical medication favoring glucose&#xD;
      uptake into tissues. It is hypothesized that empagliflozin compared to insulin specifically&#xD;
      reduces H2O2 concentrations in skeletal muscle of patients with T2DM, because it leads to&#xD;
      excretion of glucose and lower glucose uptake in skeletal muscle (22), while insulin shifts&#xD;
      the major part of excess glucose into skeletal muscle cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 27, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skeletal muscle H202 concentration between baseline and end of treatment (EoT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective is to investigate the change in H2O2 concentration as a read out of reactive oxygen species (ROS) production in skeletal muscle biopsies from T2DM patients before and after treatment with empagliflozin or insulin glargine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives of the study are to evaluate the effect of empagliflozin and insulin glargine on glucose toxicity in skeletal muscle by investigating</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in skeletal muscle mitochondrial function (O2consumption) between baseline and EoT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skeletal muscle lipid peroxidation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in skeletal muscle lipid peroxidation between baseline and EoT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour urinary excretion rate of 8-iso PGF2a</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in 24-hour urinary excretion rate of 8-iso PGF2a between baseline and EoT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Difference in DNA methylation pattern</measure>
    <time_frame>12 weeks</time_frame>
    <description>• Difference in DNA methylation pattern between the treatment groups at EoT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma FFA levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in plasma FFA levels between baseline and end of trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Empagliflozin (Jardiance®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine (Lantus®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thus, insulin glargine doses should be adapted as follows:&#xD;
FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +3 IU FBG &gt; 8 mmol/L: +5 IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin (Jardiance®)</intervention_name>
    <description>Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia &lt; 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia &lt; 3.9 mmol/L occurs) FBG &gt; 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia &lt; 3.9 mmol/L occurs)</description>
    <arm_group_label>Empagliflozin (Jardiance®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine (Lantus®)</intervention_name>
    <description>insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L&#xD;
If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:&#xD;
FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia &lt; 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia &lt; 3.9 mmol/L occurs) FBG &gt; 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia &lt; 3.9 mmol/L occurs)</description>
    <arm_group_label>Insulin Glargine (Lantus®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfill all of the following criteria before inclusion in the study:&#xD;
&#xD;
          -  The informed consent form must be signed before any study specific tests or procedures&#xD;
             are done&#xD;
&#xD;
          -  Male or female patients aged between 40 and 70 years (including) at the first&#xD;
             screening visit&#xD;
&#xD;
          -  Patients diagnosed with T2DM&#xD;
&#xD;
          -  HbA1c between 7-9% (including)&#xD;
&#xD;
          -  Stable treatment with antidiabetic drugs over the last 4 weeks&#xD;
&#xD;
          -  Accepted background medication:&#xD;
&#xD;
               -  Metformin up to 2000 mg per day and/or&#xD;
&#xD;
               -  DPP-IV inhibitors:&#xD;
&#xD;
        Linagliptin up to 5 mg per day Sitagliptin up to 100 mg per day Vildagliptin up to 100 mg&#xD;
        per day Saxagliptin up to 5 mg per day&#xD;
&#xD;
          -  Body mass index (BMI) between 25 and 40 kg/m2 (including)&#xD;
&#xD;
          -  Ability to understand and follow study-related instructions&#xD;
&#xD;
          -  No clinical relevant abnormalities during ECG and cardiac examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are to be excluded from the study if they display any of the following criteria:&#xD;
&#xD;
          -  Unstable Angina pectoris, myocardial infarction or stroke within 1 year before&#xD;
             inclusion in the study&#xD;
&#xD;
          -  History of atrial fibrillation&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (&gt; 160/100 mmHg in three subsequent measurements -&#xD;
             mean value)&#xD;
&#xD;
          -  eGFR &lt; 60 ml/min/1.73 m2&#xD;
&#xD;
          -  Macroalbuminuria defined as ≥ 300 mg albumin / 24h urine&#xD;
&#xD;
          -  Triglyceride &gt; 250 mg/dl&#xD;
&#xD;
          -  Genetic muscle disease&#xD;
&#xD;
          -  Known coagulation disorder&#xD;
&#xD;
          -  Treatment with anti-platelet therapy and anticoagulation which cannot be paused for&#xD;
             medical reasons&#xD;
&#xD;
          -  Treatment with anticoagulants within 7 days prior to the muscle biopsy&#xD;
&#xD;
          -  Contraindications according to the local SmPC of Lantus® or Jardiance® (see Appendix&#xD;
             1)&#xD;
&#xD;
          -  History of hypersensitivity to any of the study drugs or their ingredients or to drugs&#xD;
             with similar structure or to the local anesthetic scandicaine or lidocaine&#xD;
&#xD;
          -  Addiction or other diseases that preclude the patient from appropriately assessing the&#xD;
             nature and scope as well as possible consequences of the clinical study&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women of childbearing potential unless women who meet the following criteria:&#xD;
&#xD;
               -  Post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum&#xD;
                  follicle-stimulating hormone [FSH] &gt; 40 U/mL)&#xD;
&#xD;
               -  Postoperatively (six weeks after bilateral ovariectomy with or without&#xD;
                  hysterectomy)&#xD;
&#xD;
               -  Regular and correct use of a contraceptive method with error rate &lt;1% per year&#xD;
                  such as implants, depot injections, oral contraceptives or intrauterine devices&#xD;
&#xD;
               -  Sexual abstinence&#xD;
&#xD;
               -  Vasectomy of the partner&#xD;
&#xD;
          -  Males must agree not to father a child and to refrain from donating semen or sperm&#xD;
             while participating in the study and for 90 days following discontinuation from this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Fritsche, Prof.Dr.med.</last_name>
    <phone>0049707129</phone>
    <phone_ext>80590</phone_ext>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Fritsche, Prof.Dr.med.</last_name>
      <phone>0049707129</phone>
      <phone_ext>80590</phone_ext>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>German Diabetes Center, Leibniz-Center for Diabetes Research at the Heinrich-Heine-University Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <state>North Rhine Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabine Kahl, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

